A Comparison of Healthcare Resource Utilization in EPIDIOLEX® (cannabidiol) Patients Before and After Treatment Initiation

Topic(s):

Science & Innovation Webinar

Webinar Recorded on Oct. 5, 2021
Sponsored by Greenwich Biosciences, Inc.

Please Note: This webinar is intended for US formulary decision makers only.

Health economic outcomes research is becoming more important to formulary decision makers seeking to understand the true value of therapies utilizing real-world evidence.

In this webinar, experts will share and discuss the results of a retrospective claims analysis evaluating the impact of EPIDIOLEX on healthcare resource utilization (HCRU) and cost.

Join us to review the study outcomes and gain a deeper understanding of HCRU and costs pre- and post-EPIDIOLEX initiation as part of the overall treatment regimen in patients within the United States.

Speakers:

Anup Patel, MD
Medical Director, Complex Epilepsy Clinic and Clinical Outcomes
Nationwide Children’s Hospital
Associate Professor, Clinical Pediatrics and Neurology
The Ohio State University College of Medicine
Kendra Davies, PharmD, RPh
Associate Director, Health Outcomes Liaison
Greenwich Biosciences

This webinar is sponsored, developed and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by: